Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 9

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 9
---
​ | ●Positive full results from the BATURA Phase IIIb trial ofAirsuprademonstrated a 47% reduction (5.1%, 9.1%, hazard ratio 0.53; 95% CI, 0.39-0.73; p<0.001) in the risk of severe exacerbations in mild asthma compared with albuterol alone. In a key secondary endpoint, adults and adolescents ages 12 and older receivingAirsuprahad 63% lower exposure to total systemic corticosteroids (SCS) (p<0.001) over the treatment period compared with albuterol-alone. Similar reductions in all primary and secondary endpoints were seen in a prespecified subgroup of adult patients (≥18 years) on treatment. |

BioPharmaceuticals – V&I IVX-A12

| Programme update​ | NCT06481579 
 April 2025  | ●The Phase II trial to characterise safety and immunogenicity in adults 60 years of age and older has completed, and IVX-A12 was shown to be well-tolerated and immunogenic. AstraZeneca has identified opportunities to further enhance the vaccine, and is now progressing the improved RSV/hMPV combination. |

Rare Disease Alexion, AstraZeneca Rare Disease, presented new data at the European Hematology Association Congress 2025, since prior earnings. Nine abstracts were presented in rare haematology, in both PNH and HSCT-TMA. gefurulimab

18

| ​​                 | ​​               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Phase III readout​ | PREVAILJuly 2025 | ●Positive high-level results from a global, randomised, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis (gMG) showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo. |

anselamimab

| ​​                 | ​​​                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Phase III readout​ | CARES ProgrammeJuly 2025​ | ●High-level results from the CARES (301/2) Phase III clinical programme showed that ansel